Nasdaq

Recursion Pharmaceuticals to Report Q4 Earnings: What's in the Cards?

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...
TechCrunch

How Ricursive Intelligence raised $335M at a $4B valuation in 4 months

The co-founders of startup Ricursive Intelligence seemed destined to be co-founders. Anna Goldie, CEO, and Azalia Mirhoseini, CTO, are so well-known in the AI community that they were among those AI ...
thecooldown

Battery company announces 'game-changer' milestone that could make EV range anxiety a thing of the past: 'Marks a pivotal inflection point'

Boston-based Factorial has landed the strategic partnership and investments it said is needed to bring a high-performing electric vehicle battery to market by 2027. Late last year, the company ...
The New York Times

Silicon Valley Wants to Build A.I. That Can Improve A.I. on Its Own

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...
Nasdaq

Factorial Energy Plans IPO: What It Means for QS and SLDP

The solid-state battery race is heating up. Factorial Energy, a Massachusetts-based start-up, plans to go public in mid-2026. The listing will provide $100 million in capital to advance its battery ...
IEEE

Recursive Gaussian Process-Based Safety Assurance Exploration Control in Unknown Environments

Abstract: This letter presents a novel method for environmental exploration that takes safety into account in unknown areas by using recursive Gaussian process regression (RGPR). Safety in unknown ...
Business Wire

POSCO Future M Signs MOU with U.S.-based Factorial for All-Solid-State Battery Technology Development

The two companies agreed to cooperate in the development of all-solid-state battery materials. In sample testing of materials from multiple suppliers, POSCO Future M demonstrated good rate capability.
Forbes

Recursion’s Incoming CEO Needs To Prove That AI Drug Development Can Pay Off

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...
nai500

Nvidia-Backed AI Biotech Recursion Soars 25% in a Month: Time to Buy or Beware?

Amidst the AI boom transforming various sectors, Recursion Pharmaceuticals (NASDAQ: RXRX), a previously beaten-down AI-biotech, is showing signs of a rebound. Its stock has skyrocketed 25% in the past ...
The Motley Fool

Where Will Recursion Pharmaceuticals Be in 5 Years?

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...
AOL

Where Will Recursion Pharmaceuticals Be in 5 Years?

Recursion Pharmaceuticals (NASDAQ: RXRX), a biotech focused on artificial intelligence (AI), became a publicly traded company in 2021 -- a time when AI did not grab nearly as much attention (if any at ...